---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-039875"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:13:39.711948+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma Q3 net loss $57.8M; cash $306.5M; Renovacor acquisition, LAD-I/FA filings on track

## Summary
- Net loss $57.8M ($0.87/sh) vs $50.1M in Q3 2021; R&D expenses $43.4M, G&A $15.1M.
- Cash, equivalents and investments $306.5M; after $108.2M equity offering, operational runway into 2H 2024.
- Announced all-stock acquisition of Renovacor (implied ~$2.60/sh) to extend AAV cardiac gene therapy; expected close Q1 2023.
- Danon Disease Phase 1 data positive; FDA feedback on Phase 2 pivotal design anticipated Q4 2022.
- LAD-I regulatory filing expected 1H 2023, FA filing 2H 2023; PKD Phase 1 enrollment complete, Phase 2 pivotal in 2023.

## SEC filing metadata
- accession: 0001140361-22-039875
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036122039875/0001140361-22-039875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036122039875/brhc10043730_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-039875
- JSON: https://secwatch.observer/filing/0001140361-22-039875.json
- Plain text: https://secwatch.observer/filing/0001140361-22-039875.txt

## Key facts
- Earnings Releases
  ROCKET PHARMACEUTICALS, INC. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 3, 2022, Rocket Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036122039875/0001140361-22-039875-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.